Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03562221
Other study ID # 2018/61
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 4, 2018
Est. completion date August 2027

Study information

Verified date October 2023
Source Lund University
Contact Carin A Aronsson, PhD
Phone +46708876649
Email carin.andren_aronsson@med.lu.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to investigate the impact on being on a gluten free diet the first three years of life compared to a daily intake of a probiotic supplementation or placebo on the risk of developing celiac disease autoimmunity or celiac disease in genetically susceptible children. Study participants will be randomly allocated to one of the three study groups before the age of 4 months and will remain in that group with the corresponding intervention during the three first years of life. Regular visits to a study nurse and contact with study dietician will be scheduled. The dietician will support the families in keeping the correct diet intended for each study group.


Description:

The primary hypothesis to be tested is that a strictly gluten free diet during the first three years of life with a slow introduction of gluten during the follow-up period will induce tolerance to gluten. A similar hypothesis is tested if a daily supply of two different lactobacillus (LB) strains can suppress an inflammatory response to gluten in the intestine by stimulating regulatory T-cells and reduced permeability of gluten peptides in the intestine. The secondary hypothesis tested is that celiac disease can not be prevented, but the onset of the disease will be delayed in children returning to a gluten-containing diet after the intervention period (gluten free diet) or probiotic treatment) during the first three years of life. The intervention period is 3 years and the follow-up period is further 4 years. The primary aim is to study the proportion of children who develop celiac disease autoimmunity and progression to celiac disease by the age of 3 years. Secondary aim is to study the proportion of children who developed celiac disease at the age of 7 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date August 2027
Est. primary completion date August 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 4 Months to 4 Months
Eligibility Inclusion Criteria: - Children screened positive for human leucocyte antigen (HLA) DR3-DQ2/DR3-DQ2 - Children must be enrolled to the study by 4 months of age (before gluten consumption has started). Exclusion Criteria: - Congenital chronic disorder where intervention with diet or probiotics may be affected. - Written consent from both caregivers are missing

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Gluten free diet
Controlled gluten free diet
Dietary Supplement:
Probiotics
Capsules
Placebo
Capsules

Locations

Country Name City State
Sweden Clinical Research Center (CRC), Bldng 60:11 Malmö

Sponsors (1)

Lead Sponsor Collaborator
Lund University

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of children tested positive for persistent tissue transglutaminase (tTG) autoantibodies, defined as celiac disease autoimmunity Radioligand binding assays (RBA) will be used to measure tTG autoantibodies in serum samples collected every third months up until the age of 3 years and then annually up until the age of 7 years. from 4 months of age up until 7 years of age
Secondary Number of children diagnosed with celiac disease A celiac disease diagnose will be defined by an intestinal biopsy showing a Marsh score of 2 or higher or by high levels of tTG autoantibodies (> 100 units) in at least 2 consecutive blood samples. Up until 7 years of age
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04440501 - Virtual Reality to Teach, Improve Outcomes, and Engage (VIRTUE): Virtual Reality to Improve Gluten-Free Diet Knowledge in Pediatric Celiac Disease N/A
Enrolling by invitation NCT06179121 - "Adding DNA-test for Screening of HLA-DQ2 and DQ8 to Improve Early Diagnosis of Celiac Disease"
Recruiting NCT06324539 - Validation of a New Innovative Method for Specific Marker Detection in Celiac Disease
Completed NCT06359613 - Efficacy Assessment of Gluten Free Cupcakes N/A
Active, not recruiting NCT05548166 - Development of CELIAC-Q KIDS: A Patient-Reported Outcome Measure for Pediatric Celiac Disease
Recruiting NCT04014660 - Prevention av Autoimmunitet Med Laktobaciller N/A
Not yet recruiting NCT04019223 - Anti-Tissue Transglutaminase IgA Antibodies
Completed NCT03966625 - Serological Identification of Celiac Disease in Kids
Not yet recruiting NCT03244254 - Intestinal Fatty Acid-binding Protein (I-FABP) Levels in Pediatric Celiac Patients N/A
Recruiting NCT05132725 - Carbohydrate Counting and DASH Intervention Among Children With Diabetes and Celiac Disease. N/A
Enrolling by invitation NCT05084937 - Celiac Disease in Childhood-Adulthood Transition N/A
Active, not recruiting NCT04593888 - Gluten Reduction and Risk of Celiac Disease N/A
Recruiting NCT06007898 - Supporting Children and Young People to Live Well With Coeliac Disease N/A
Recruiting NCT06364735 - Entities and Variables Related to Catch-up Growth
Completed NCT04272983 - Population Study of the Prevalence of Celiac Disease and Other Gluten-dependent Disorders in Children and Adolescents
Not yet recruiting NCT06149507 - Effect of Acetaminophen Versus Ibuprofen in Treating Recurrent Apthous Ulcers in Pediatric Celiac Disease Phase 4
Completed NCT04240340 - Experiences of Disclosure in Adolescents With Coeliac Disease
Completed NCT03176095 - Celiac Disease Prevention With Probiotics N/A
Active, not recruiting NCT06038344 - Influence of a Gluten Free Food Guide on Diet Quality and Adherence to the GFD in Youth With Celiac Disease N/A
Completed NCT04533776 - Support for Adolescents With Celiac Disease N/A